Bacterial lipopolysaccharides variably modulate in vitro biofilm formation of Candida species.
The objective of this study was to evaluate the effect of the bacterial endotoxin LPS on Candida biofilm formation in vitro. The effect of the LPS of Pseudomonas aeruginosa, Klebsiella pneumoniae, Serratia marcescens and Salmonella typhimurium on six different species of Candida, comprising Candida albicans ATCC 90028, Candida glabrata ATCC 90030, Candida krusei ATCC 6258, Candida tropicalis ATCC 13803, Candida parapsilosis ATCC 22019 and Candida dubliniensis MYA 646, was studied using a standard biofilm assay. The metabolic activity of in vitro Candida biofilms treated with LPS at 90 min, 24 h and 48 h was quantified by XTT reduction assay. Viable biofilm-forming cells were qualitatively analysed using confocal laser scanning microscopy (CLSM), while scanning electron microscopy (SEM) was employed to visualize the biofilm structure. Initially, adhesion of C. albicans was significantly stimulated by Pseudomonas and Klebsiella LPS. A significant inhibition of Candida adhesion was noted for the following combinations: C. glabrata with Pseudomonas LPS, C. tropicalis with Serratia LPS, and C. glabrata, C. parapsilosis or C. dubliniensis with Salmonella LPS (P<0.05). After 24 h of incubation, a significant stimulation of initial colonization was noted for the following combinations: C. albicans/C. glabrata with Klebsiella LPS, C. glabrata/C. tropicalis/C. krusei with Salmonella LPS. In contrast, a significant inhibition of biofilm formation was observed in C. glabrata/C. dubliniensis/C. krusei with Pseudomonas LPS, C. krusei with Serratia LPS, C. dubliniensis with Klebsiella LPS and C. parapsilosis/C. dubliniensis /C. krusei with Salmonella LPS (P<0.05). On further incubation for 48 h, a significant enhancement of biofilm maturation was noted for the following combinations: C. glabrata/C. tropicalis with Serratia LPS, C. dubliniensis with Klebsiella LPS and C. glabrata with Salmonella LPS, and a significant retardation was noted for C. parapsilosis/C. dubliniensis/C. krusei with Pseudomonas LPS, C. tropicalis with Serratia LPS, C. glabrata/C. parapsilosis/C. dubliniensis with Klebsiella LPS and C. dubliniensis with Salmonella LPS (P<0.05). These findings were confirmed by SEM and CLSM analyses. In general, the inhibition of the biofilm development of LPS-treated Candida spp. was accompanied by a scanty architecture with a reduced numbers of cells compared with the profuse and densely colonized control biofilms. These data are indicative that bacterial LPSs modulate in vitro Candida biofilm formation in a species-specific and time-dependent manner. The clinical and the biological relevance of these findings have yet to be explored.
Bandara
H M H N
HMHN
Oral Biosciences, Faculty of Dentistry, University of Hong Kong, 5/F Prince Philip Dental Hospital, 34 Hospital Road, Sai Ying Pun, Hong Kong SAR.
Lam
O L T
OLT
Oral Rehabilitation, Faculty of Dentistry, University of Hong Kong, Sai Ying Pun, Hong Kong SAR.
Watt
R M
RM
Oral Biosciences, Faculty of Dentistry, University of Hong Kong, 5/F Prince Philip Dental Hospital, 34 Hospital Road, Sai Ying Pun, Hong Kong SAR.
Jin
L J
LJ
Periodontology, Faculty of Dentistry, University of Hong Kong, Sai Ying Pun, Hong Kong SAR.
Samaranayake
L P
LP
Oral Biosciences, Faculty of Dentistry, University of Hong Kong, 5/F Prince Philip Dental Hospital, 34 Hospital Road, Sai Ying Pun, Hong Kong SAR.
D000898:Antibiosis; D018441:Biofilms / Q000254:growth & development*; D002175:Candida / Q000254:growth & development / Q000378:metabolism / Q000502:physiology*; D002448:Cell Adhesion; D002473:Cell Wall / Q000737:chemistry*; D006090:Gram-Negative Bacteria / Q000737:chemistry*; D006801:Humans; D008070:Lipopolysaccharides / Q000302:isolation & purification / Q000378:metabolism*; D050296:Microbial Viability; D018613:Microscopy, Confocal; D010084:Oxidation-Reduction; D013778:Tetrazolium Salts / Q000378:metabolism; D013997:Time Factors
D008070:Lipopolysaccharides; D013778:Tetrazolium Salts; C059087:2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide